The Technical Analyst
Immix Biopharma, Inc. [IMMX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Immix Biopharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.74% $2.13
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 56.22 mill |
| EPS: | -0.890 |
| P/E: | -2.39 |
| Earnings Date: | May 29, 2024 |
| SharesOutstanding: | 26.40 mill |
| Avg Daily Volume: | 0.286 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.39 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.41x |
| Company: PE -2.39 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.010 (-52.60%) $-1.120 |
| Date: 2024-04-22 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.824 - 2.44 ( +/- 14.37%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-11 | Hsu Jason | Buy | 31 000 | Common Stock |
| 2023-12-08 | Hsu Jason | Buy | 25 000 | Common Stock |
| 2023-08-14 | Morris Gabriel S | Buy | 293 000 | Stock Options |
| 2023-08-14 | Rachman Ilya M | Buy | 293 000 | Stock Options |
| 2023-09-15 | Hsu Jason | Buy | 7 000 | Common Stock |
| INSIDER POWER |
|---|
| 99.99 |
| Last 65 transactions |
| Buy: 7 237 723 | Sell: 879 400 |
Forecast:
16:00 - $2.13
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.13
Forecast 2: 16:00 - $2.13
Forecast 3: 16:00 - $2.13
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.13 (-2.74% ) |
| Volume | 0.191 mill |
| Avg. Vol. | 0.286 mill |
| % of Avg. Vol | 66.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMMX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $3.27 | N/A | Active |
|---|
IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Latest Press Releases
2024-04-18 09:32:00 - Press Release
Immix Biopharma On Track To Dose Nxc-201 Patients In United States
Scheduling u.s. site initiation visits april and may 2024 on track to dose relapsed/refractory al amyloidosis patients with car-t nxc-201 at new york city lead site and other leading u.s. sites mid-2024 no change in patient enrollment timing los angeles, april 18, 2024 (globe newswire) -- immix biopharma, inc. (nasdaq: immx) (“immixbio”, “company”, “we” or “us” or “immx”), a clinical-stage biopharmaceutical company trailblazing cell therapies in al amyloidosis and other autoimmune diseases, today announced that immix biopharma is on track to dose nxc-201 patients in the u.s. with no change in patient enrollment timing. “we are on track to dose relapsed/refractory al amyloidosis nxc-201 patients at our new york city lead site and other leading u...
2024-04-15 09:36:00 - Press Release
Immix Biopharma Announces Late-breaking Nxc-201 Clinical Data Abstract Accepted For Oral Presentation At The 27th Annual Meeting Of The American Society Of Gene And Cell Therapy (asgct)
Los angeles, april 15, 2024 (globe newswire) -- immix biopharma, inc. (nasdaq: immx) (“immixbio”, “company”, “we” or “us” or “immx”), a clinical-stage biopharmaceutical company trailblazing cell therapies in al amyloidosis and other autoimmune diseases, today announced that updated nxc-201 clinical data has been selected for presentation at the upcoming 27th annual meeting of the american society of gene & cell therapy (asgct) to be held in baltimore may 7-11, 2024.
2024-03-20 09:46:00 - Press Release
Immix Biopharma Announces Major Comprehensive Cancer Center As Lead Site For Nxc-201 Al Amyloidosis Clinical Trial
Los angeles, ca, march 20, 2024 (globe newswire) -- immix biopharma, inc. (nasdaq: immx) (“immixbio”, “company”, “we” or “us” or “immx”), a clinical-stage biopharmaceutical company trailblazing cell therapies in al amyloidosis and other autoimmune diseases, today announced memorial sloan kettering cancer center as lead clinical site for its nxc-201 relapsed/refractory al amyloidosis multi-site clinical trial.
2024-03-05 09:35:00 - Press Release
Immix Biopharma Announces “be Proactive In Al” Al Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory al amyloidosis patients in the united states today in their own words hear from the ~30,000 relapsed or refractory al amyloidosis patients in the united states today in their own words
2024-02-21 09:31:00 - Press Release
Immix Biopharma 12 Month Review Progress Update
Los angeles, feb. 21, 2024 (globe newswire) -- immix biopharma, inc. (nasdaq: immx), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.
Latest News
2023-12-03 02:02:03 - Seeking Alpha
Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status
Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural killer cell therapy, which has shown a 95% overall response rate in patients with multiple myeloma. They also have a tissue-specific platform called iMX-110, which is being assessed in early-stage studies for sarcoma and colorectal cancer.
2023-11-30 09:46:00 - GlobeNewsWire
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit.
2023-11-28 10:32:06 - Zacks Investment Research
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
Immix Biopharma, Inc. (IMMX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2023-11-22 12:47:43 - Zacks Investment Research
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.
2023-09-22 13:31:16 - Zacks Investment Research
Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy
Immix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of amyloid light chain (AL) Amyloidosis.
2023-09-07 10:38:53 - InvestorPlace
The 3 Best Speculative Stocks to Buy Now: September 2023
A high-ranking official at the Federal Reserve has indicated that the US central bank is planning to maintain its benchmark interest rate during its September policy meeting. This decision comes in response to recent economic data, which, according to the official, does not warrant any immediate need for additional monetary tightening.
2022-12-16 07:00:37 - InvestorPlace
3 Penny Stocks With the Potential to 10X in 2023
While 2022 has been a terrible year for investors looking for penny stocks to buy, 2023 might not be as bad. The economy went through a choppy year, and particularly volatile assets such as penny stocks sold off painfully.
2022-12-15 13:40:59 - PennyStocks
Penny Stocks To Buy? 4 To Watch Before Next Week
2022-05-20 18:11:19 - PennyStocks
Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market
Are these biotech penny stocks on your watchlist right now? The post Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-02-01 11:36:36 - InvestorPlace
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI appeared first on InvestorPlace.